var data={"title":"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Rashmi Chugh, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Michael S Sabel, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Mary Feng, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Robert Maki, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Daniel F Hayes, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)</a></dd><dd><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Thomas F DeLaney, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Sadhna R Vora, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Wenliang Chen, MD, PhD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Breast sarcomas are rare, histologically heterogeneous nonepithelial malignancies that arise from the connective tissue within the breast [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/1\" class=\"abstract_t\">1</a>]. They can develop de novo (primary), after radiation therapy (RT), or in the setting of lymphedema of the arm or breast after treatment of another malignancy (therapy related, secondary) [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/2-6\" class=\"abstract_t\">2-6</a>]. Although the clinical features of breast sarcoma mimic those of breast carcinoma in some ways, therapy and prognosis differ dramatically. </p><p>This topic review will cover the epidemiology, risk factors, clinical features, diagnosis and staging of breast sarcoma. Treatment and prognosis are discussed elsewhere as are other nonepithelial breast tumors including breast lymphomas, phyllodes tumors (including cystosarcoma phyllodes), and desmoid tumors of the breast. (See <a href=\"topic.htm?path=breast-sarcoma-treatment\" class=\"medical medical_review\">&quot;Breast sarcoma: Treatment&quot;</a> and <a href=\"topic.htm?path=breast-lymphoma\" class=\"medical medical_review\">&quot;Breast lymphoma&quot;</a> and <a href=\"topic.htm?path=desmoid-tumors-epidemiology-risk-factors-molecular-pathogenesis-clinical-presentation-diagnosis-and-local-therapy#H12\" class=\"medical medical_review\">&quot;Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy&quot;, section on 'Breast desmoids'</a>.)</p><p class=\"headingAnchor\" id=\"H3320653\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Breast sarcomas are rare; they account for less than 1 percent of all breast malignancies [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/7\" class=\"abstract_t\">7</a>] and &lt;5 percent of all soft tissue sarcomas [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/8\" class=\"abstract_t\">8</a>]. In data compiled from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute, the annual incidence of breast sarcomas was 4.6 cases per million women [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/9\" class=\"abstract_t\">9</a>]. </p><p>The specific incidence of secondary, therapy-related breast sarcomas is difficult to discern. Secondary or treatment-related breast sarcomas most frequently arise following breast cancer treatment with RT. However, the absolute magnitude of the risk of a secondary breast sarcoma in women who undergo RT for breast cancer appears to be small (<a href=\"image.htm?imageKey=ONC%2F61730\" class=\"graphic graphic_table graphicRef61730 \">table 1</a>). </p><p>The specific sarcoma subtype that is associated most strongly with treatment for a previous breast cancer is angiosarcoma. In a population-based study in Los Angeles County, the adjusted relative risk of developing an angiosarcoma for women with a prior diagnosis of breast cancer compared with women without breast cancer was 59 (95% CI 22-153) [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/10\" class=\"abstract_t\">10</a>]. Furthermore, women who receive RT as a component of breast cancer treatment have a 9- to 16-fold increase in the relative risk of developing an angiosarcoma relative to those treated with other modalities [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/6,11\" class=\"abstract_t\">6,11</a>]. However, despite these high relative risks, the absolute magnitude of risk for a treatment-related angiosarcoma after RT remains small (<a href=\"image.htm?imageKey=ONC%2F61730\" class=\"graphic graphic_table graphicRef61730 \">table 1</a>). The association between ionizing RT and breast sarcomas is discussed in more detail below. (See <a href=\"#H30564621\" class=\"local\">'Ionizing radiation'</a> below.)</p><p>The average age at presentation is 45 to 50 years (range 17 to 89) [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/7,9,12-15\" class=\"abstract_t\">7,9,12-15</a>]. The vast majority of primary breast sarcomas arise in women, although cases are described in men [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/16\" class=\"abstract_t\">16</a>]. Men accounted for 1.5 percent of cases of breast sarcoma in a compilation of published reports [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/17\" class=\"abstract_t\">17</a>]. </p><p>Primary breast angiosarcomas tend to occur in somewhat younger women; the average age at diagnosis is under 40 years in most series [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/10,18-21\" class=\"abstract_t\">10,18-21</a>]. In contrast, the average age of occurrence for treatment-related angiosarcomas is older (median 64, range 44 to 84 years) [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/18,20,22\" class=\"abstract_t\">18,20,22</a>]. This may be related, at least in part, from the increased prevalence of epithelial breast cancer in older patients. Information about the latency period between RT and the development of radiation-induced breast sarcomas is found below. (See <a href=\"#H30564621\" class=\"local\">'Ionizing radiation'</a> below.) </p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A causative factor for the formation of primary soft tissue sarcomas cannot be identified in many patients with primary breast sarcomas [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/23\" class=\"abstract_t\">23</a>]. In contrast, secondary breast sarcomas are associated with prior RT and conditions causing chronic lymphedema [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/2-6,11,24\" class=\"abstract_t\">2-6,11,24</a>]. There is no proven association between breast implants and breast sarcomas in humans. (See <a href=\"topic.htm?path=complications-of-reconstructive-and-aesthetic-breast-surgery#H24299623\" class=\"medical medical_review\">&quot;Complications of reconstructive and aesthetic breast surgery&quot;, section on 'Anaplastic large cell lymphoma'</a> and <a href=\"topic.htm?path=implant-based-breast-reconstruction-and-augmentation#H1616409128\" class=\"medical medical_review\">&quot;Implant-based breast reconstruction and augmentation&quot;, section on 'Concerns over breast implants'</a>.)</p><p class=\"headingAnchor\" id=\"H30564621\"><span class=\"h2\">Ionizing radiation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ionizing radiation is a well-documented risk factor for a secondary breast sarcoma. The classification of a tumor as a radiation-induced sarcoma generally requires that the following criteria be met [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/25\" class=\"abstract_t\">25</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evidence of an initial malignant tumor of a different histology than the putative radiation-induced sarcoma</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Development of the sarcoma in an irradiated field</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A prolonged latency period (typically &gt;4 years) between the two malignancies</p><p/><p>Secondary or treatment-related breast sarcomas most frequently arise following breast cancer treatment with RT, either as part of breast conserving therapy or after mastectomy [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/25-30\" class=\"abstract_t\">25-30</a>]. However, secondary breast sarcomas can also follow RT for other malignancies (eg, lymphoma) when the breast <span class=\"nowrap\">and/or</span> chest wall are included in the irradiated field [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/4\" class=\"abstract_t\">4</a>]. </p><p>As with sarcomas at any location, the risk of a radiation-induced breast sarcoma generally increases with higher doses of RT [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/27,31\" class=\"abstract_t\">27,31</a>]. In addition, the risk of secondary sarcoma is higher when patients are irradiated as children than as adults, particularly in those receiving both RT and chemotherapy [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/32\" class=\"abstract_t\">32</a>]. (See <a href=\"topic.htm?path=second-malignancies-after-treatment-of-classical-hodgkin-lymphoma#H30\" class=\"medical medical_review\">&quot;Second malignancies after treatment of classical Hodgkin lymphoma&quot;, section on 'Bone and soft tissue cancer'</a> and <a href=\"topic.htm?path=pathogenetic-factors-in-soft-tissue-and-bone-sarcomas#H27\" class=\"medical medical_review\">&quot;Pathogenetic factors in soft tissue and bone sarcomas&quot;, section on 'RT and chemotherapy'</a>.)</p><p class=\"headingAnchor\" id=\"H9239667\"><span class=\"h3\">Breast cancer survivors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The early detection of breast cancer through mammographic screening and improvements in adjuvant therapy have increased the number of breast cancer survivors who are potentially cured of their disease and live long enough to develop late effects of treatment, which includes secondary malignancies such as therapy-related sarcomas. (See <a href=\"topic.htm?path=patterns-of-relapse-and-long-term-complications-of-therapy-in-breast-cancer-survivors#H541709403\" class=\"medical medical_review\">&quot;Patterns of relapse and long-term complications of therapy in breast cancer survivors&quot;, section on 'Radiation therapy'</a>.)</p><p>Although women who undergo RT for breast cancer have an increased risk of in-field sarcomas that persists for 20 to 30 years, the absolute magnitude of the risk appears to be small (<a href=\"image.htm?imageKey=ONC%2F61730\" class=\"graphic graphic_table graphicRef61730 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/2,6,11,33-37\" class=\"abstract_t\">2,6,11,33-37</a>]. The average latency period for secondary sarcomas after RT for breast carcinoma is approximately 10 to 11 years, but it may be as long as 44 years and as short as six months [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/3-5,33,38-40\" class=\"abstract_t\">3-5,33,38-40</a>]. The latency period is shorter for angiosarcomas, which tend to occur four to eight years post-treatment [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/5,10,22,41-44\" class=\"abstract_t\">5,10,22,41-44</a>]. </p><p>It is not known whether newer radiation techniques such as intensity modulated RT (IMRT, which decreases the volume of breast tissue exposed to high RT doses, but increases the volume exposed to low doses of irradiation [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/45\" class=\"abstract_t\">45</a>]) or hypofractionated regimens may influence the risk of a radiation-induced sarcoma. (See <a href=\"topic.htm?path=radiation-therapy-techniques-for-newly-diagnosed-non-metastatic-breast-cancer\" class=\"medical medical_review\">&quot;Radiation therapy techniques for newly diagnosed, non-metastatic breast cancer&quot;</a>.)</p><p>The indisputable benefit of RT in the treatment of breast carcinoma largely outweighs the small risk of a treatment-related sarcoma [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/6\" class=\"abstract_t\">6</a>]. Nevertheless, the risk is real, and in some cases, it may impact on a patient's choice of therapy. As an example, women who have inherited mutations in the ataxia telangiectasia mutated gene, which are associated with an increased risk of radiation-induced sarcoma, may choose to avoid breast conserving therapy, opting instead for mastectomy. (See <a href=\"#H4672806\" class=\"local\">'Inherited conditions'</a> below and <a href=\"topic.htm?path=adjuvant-radiation-therapy-for-women-with-newly-diagnosed-non-metastatic-breast-cancer\" class=\"medical medical_review\">&quot;Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H751986\"><span class=\"h2\">Lymphedema</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic arm or breast edema increases the risk of sarcoma after breast cancer treatment, particularly angiosarcoma. Angiosarcomas can develop in extremities with chronic lymphedema of any etiology [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/46\" class=\"abstract_t\">46</a>]. </p><p>Lymphangiosarcomas of the upper extremity, breast, and axilla arising in women with chronic lymphedema after breast cancer therapy were initially described by Stewart and Treves, and this syndrome is now designated Stewart-Treves syndrome [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/24\" class=\"abstract_t\">24</a>]. Such women typically present with longstanding extensive arm edema after mastectomy and axillary lymph node dissection, although it may occur after RT alone (due to axillary lymph node sclerosis) and is most common in patients undergoing both axillary RT and surgery. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-peripheral-lymphedema\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of peripheral lymphedema&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4672806\"><span class=\"h2\">Inherited conditions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As with other soft tissue sarcomas, there are some predisposing genetic conditions for a breast sarcoma, including Li-Fraumeni syndrome, familial adenomatous polyposis and its variants, or neurofibromatosis type 1, but these are only rarely identified in patients with a breast sarcoma [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=pathogenetic-factors-in-soft-tissue-and-bone-sarcomas#H2\" class=\"medical medical_review\">&quot;Pathogenetic factors in soft tissue and bone sarcomas&quot;, section on 'Genetic predisposition'</a> and <a href=\"topic.htm?path=li-fraumeni-syndrome\" class=\"medical medical_review\">&quot;Li-Fraumeni syndrome&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of familial adenomatous polyposis&quot;</a> and <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis#H1815266\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis&quot;, section on 'Soft tissue sarcomas'</a>.)</p><p class=\"headingAnchor\" id=\"H4672598\"><span class=\"h2\">Environmental factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Besides ionizing irradiation, environmental exposures linked to sarcomas in general include arsenic compounds, vinyl chloride, herbicides, immunosuppressive agents, and in the case of Kaposi's sarcoma, HIV and human herpes virus type 8. (See <a href=\"topic.htm?path=aids-related-kaposi-sarcoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=pathogenetic-factors-in-soft-tissue-and-bone-sarcomas#H27\" class=\"medical medical_review\">&quot;Pathogenetic factors in soft tissue and bone sarcomas&quot;, section on 'RT and chemotherapy'</a> and <a href=\"topic.htm?path=pathogenetic-factors-in-soft-tissue-and-bone-sarcomas#H30\" class=\"medical medical_review\">&quot;Pathogenetic factors in soft tissue and bone sarcomas&quot;, section on 'Industrial chemicals'</a>.)</p><p>Although exposure to chemotherapy, particularly alkylating agents, has been implicated in radiation-induced sarcomas, a systematic review of nine studies found no evidence that chemotherapy is a contributing risk factor for a radiation-induced breast sarcoma, at least in adults [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H529562\"><span class=\"h1\">HISTOLOGIC CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As with other non-breast soft tissue sarcomas, primary breast sarcomas are histologically heterogeneous. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H12227072\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'Histopathology'</a>.)</p><p>Histologic review by an experienced soft tissue pathologist is critical in making the diagnosis and determining histologic subtype. Evaluation of subtype distribution in the breast is limited by the rarity of the disease, but also by heterogeneity in the way these tumors have been classified [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/7,9\" class=\"abstract_t\">7,9</a>]. Disparate classification schemes have often been used, obscuring distinctions in clinical course and prognosis among the different histologic entities, as illustrated by the following observations: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some authors exclude cystosarcoma phyllodes (malignant phyllodes tumor) from breast sarcoma studies because these tumors have a benign epithelial component in addition to a malignant mesenchymal component. Others classify malignant phyllodes tumors as a subtype of breast sarcoma because of the similar survival and clinical course [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/7,9,12,48\" class=\"abstract_t\">7,9,12,48</a>]. Phyllodes tumors of the breast are considered separately. (See <a href=\"topic.htm?path=phyllodes-tumors-of-the-breast\" class=\"medical medical_review\">&quot;Phyllodes tumors of the breast&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some series include carcinosarcomas of the breast (metaplastic carcinoma), which represent various combinations of poorly differentiated ductal adenocarcinoma, mesenchymal (sarcomatous), and other epithelial cell (eg, squamous) components. However, most clinicians classify and treat these tumors as a variant of ductal adenocarcinoma. (See <a href=\"topic.htm?path=pathology-of-breast-cancer#H9\" class=\"medical medical_review\">&quot;Pathology of breast cancer&quot;, section on 'Metaplastic carcinoma'</a>.)</p><p/><p>In general, fibrosarcomas, angiosarcomas, and undifferentiated pleomorphic sarcomas (formerly included in a broad category of soft tissue sarcomas that were termed malignant fibrous histiocytoma [MFH], which was the most common subtype of soft tissue sarcoma) comprise the major subtypes. Subsets of <span class=\"nowrap\">undifferentiated/unclassified</span> soft tissue sarcomas include the pleomorphic, round cell, and spindle cell variants. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H12227072\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'Histopathology'</a>.)</p><p>For example, in a series of 25 patients with primary breast sarcomas, the histologic subtype distribution was as follows [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/13\" class=\"abstract_t\">13</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fibrosarcoma &ndash; 24 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Angiosarcoma &ndash; 24 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Undifferentiated pleomorphic sarcoma &ndash; 24 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Myxofibrosarcoma &ndash; 12 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leiomyosarcoma &ndash; 8 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemangiopericytoma and osteosarcoma &ndash; 4 percent each </p><p/><p>In many series, particularly those with a high percentage of therapy-related breast sarcomas, angiosarcomas are the most common tumor type [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/14,15,49\" class=\"abstract_t\">14,15,49</a>]. Angiosarcomas comprise almost one-half of all histologic subtypes in series of secondary breast sarcomas [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/6,11\" class=\"abstract_t\">6,11</a>].</p><p>Angiosarcomas are sometimes referred to either as lymphangiosarcomas or hemangiosarcomas (derived from lymphatic and capillary endothelium, respectively). As this distinction can be quite difficult histologically and not always clearly defined, both subtypes will be referred to collectively as angiosarcomas for the purpose of this review. </p><p>Angiosarcomas have a poor prognosis relative to other subtypes; they behave in a locally aggressive fashion and often metastasize to distant sites. In contrast, there is no apparent prognostic relevance for other histologic subtypes. (See <a href=\"topic.htm?path=breast-sarcoma-treatment#H12210134\" class=\"medical medical_review\">&quot;Breast sarcoma: Treatment&quot;, section on 'Outcomes'</a>.)</p><p class=\"headingAnchor\" id=\"H10858421\"><span class=\"h2\">Grading</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The features that are used to assign histologic grade of differentiation are the extent of tissue differentiation, the mitotic count, presence or absence of necrosis, cellularity, and pleomorphism. Histologic grade is an important prognostic factor for soft tissue sarcomas, including those arising in the breast. One exception is that the importance of grade in the prognosis of angiosarcoma is disputed. Although some series indicate a better prognosis for low-grade tumors [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/50-53\" class=\"abstract_t\">50-53</a>], others do not [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/21,54\" class=\"abstract_t\">21,54</a>], and grading is generally not recommended for angiosarcomas [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/55,56\" class=\"abstract_t\">55,56</a>]. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H7800294\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'Histologic grade'</a> and <a href=\"topic.htm?path=breast-sarcoma-treatment#H12210134\" class=\"medical medical_review\">&quot;Breast sarcoma: Treatment&quot;, section on 'Outcomes'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL FEATURES AND DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A breast sarcoma most often presents as a unilateral, well-defined, large, painless, firm mass within the breast; they are rarely bilateral. They are usually larger in size than are epithelial breast cancers (median size 5 to 6 cm) and are often characterized by a rapid increase in size [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/5,9,57\" class=\"abstract_t\">5,9,57</a>] </p><p>Breast skin and the nipple-areola complex are only rarely involved by breast sarcomas [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/58-60\" class=\"abstract_t\">58-60</a>]. However, angiosarcomas are the exception; they may be associated with skin thickening, erythema, or skin discoloration with an overlying bluish tint [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/9,41\" class=\"abstract_t\">9,41</a>]. These findings are sometimes mistaken for cellulitis or a hematoma. (See <a href=\"#H4672367\" class=\"local\">'Differential diagnosis'</a> below.)</p><p>Therapy-related angiosarcomas have a distinct appearance, presenting as single or multiple ecchymotic macular or purplish papular cutaneous lesions in the breast (<a href=\"image.htm?imageKey=ONC%2F86979\" class=\"graphic graphic_picture graphicRef86979 \">picture 1</a>) or an edematous upper extremity. Clinically, breast sarcomas often exhibit more rapid growth than do epithelial breast cancers. As with other breast sarcomas, tumor size can be quite large, ranging from 1.5 to 30 cm (median 5 to 6 cm) [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/7,9,13,51,61\" class=\"abstract_t\">7,9,13,51,61</a>].</p><p class=\"headingAnchor\" id=\"H4675516\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A breast sarcoma may be suspected based upon physical examination or imaging. However, the findings may be similar to those of a primary breast cancer or a benign entity, and accurate tissue diagnosis requires a biopsy. </p><p class=\"headingAnchor\" id=\"H11242979\"><span class=\"h3\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Findings on mammography are nonspecific; calcifications and spiculation are usually absent. In a series of 24 women with primary breast sarcomas, the predominant mammographic finding was a noncalcified oval mass with indistinct margins [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/62\" class=\"abstract_t\">62</a>]. Some tumors may be mistaken for benign lesions such as fibroadenomas [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/23,63\" class=\"abstract_t\">23,63</a>]. The mammogram may be negative even in the setting of a large palpable mass or skin changes [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/64-67\" class=\"abstract_t\">64-67</a>]. Therapy-related sarcomas may be more difficult to detect mammographically because of post-surgical or post-radiation changes, but nodular masses may be present (<a href=\"image.htm?imageKey=RADIOL%2F86977\" class=\"graphic graphic_diagnosticimage graphicRef86977 \">image 1</a>). </p><p>Once the tumor is diagnosed as a breast sarcoma, breast magnetic resonance imaging (MRI) is sometimes helpful to more closely examine disease extent preoperatively, particularly in locally advanced tumors near the chest wall. Malignant tumors display rapid contrast enhancement with washout characteristics [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/62,65,68-71\" class=\"abstract_t\">62,65,68-71</a>]. The borders are often indistinct and enhancement is inhomogeneous [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/62\" class=\"abstract_t\">62</a>]. The MRI appearance of an angiosarcoma is characteristic; with low signal intensity on T1-weighted images, but high signal intensity on heavily T2-weighted images, suggesting the presence of vascular channels containing slow flowing blood [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/72,73\" class=\"abstract_t\">72,73</a>]. </p><p>MRI can also provide information on the extent of disease within the skin (<a href=\"image.htm?imageKey=RADIOL%2F86977\" class=\"graphic graphic_diagnosticimage graphicRef86977 \">image 1</a>) as well as presence or absence of involvement of the deep fascia and pectoralis muscle, which is important in planning the surgical approach [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/65,68-70,72\" class=\"abstract_t\">65,68-70,72</a>]. However, as with other imaging modalities, MRI can underestimate the extent of disease.</p><p class=\"headingAnchor\" id=\"H3321882\"><span class=\"h3\">Biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Incisional, excisional, or core needle biopsy all can provide a definitive diagnosis. Core biopsy is generally considered the procedure of choice. If sarcoma is suspected, fine needle aspiration (FNA) is strongly discouraged as it has a low diagnostic accuracy for sarcoma and a false negative result may lead to a delay in diagnosis. In addition, determination of histologic subtype and grade is not possible with FNA. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H12227177\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'Biopsy'</a>.)</p><p>For cutaneous lesions concerning for angiosarcoma, multiple punch biopsies of the skin may provide a diagnosis (<a href=\"image.htm?imageKey=ONC%2F86926\" class=\"graphic graphic_picture graphicRef86926 \">picture 2</a>). The available data are insufficient to assess the accuracy of this approach. The specimen should be taken from the darkest and most infiltrated area.</p><p class=\"headingAnchor\" id=\"H4672563\"><span class=\"h3\">Laboratory studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum chemistries and tumor markers are of no value in establishing a diagnosis of a breast sarcoma.</p><p class=\"headingAnchor\" id=\"H4672367\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of a primary breast sarcoma includes other primary breast tumors, including inflammatory breast cancer, recurrent ductal adenocarcinoma, phyllodes tumor of the breast, breast lymphoma, metastases to the breast from other primary sites, and other benign breast disorders such as sclerosing adenosis or fibroadenoma. Angiosarcomas with skin discoloration may be mistaken for cellulitis or a breast hematoma. Patients with suspicious findings of discoloration should have follow-up clinical evaluation within two weeks. If skin findings have not improved or have worsened, then immediate punch biopsy should be performed. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-features-diagnosis-and-staging-of-newly-diagnosed-breast-cancer\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and staging of newly diagnosed breast cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=inflammatory-breast-cancer-clinical-features-and-treatment\" class=\"medical medical_review\">&quot;Inflammatory breast cancer: Clinical features and treatment&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-locoregional-recurrence-of-breast-cancer-after-breast-conserving-therapy\" class=\"medical medical_review\">&quot;Management of locoregional recurrence of breast cancer after breast conserving therapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-locoregional-recurrence-of-breast-cancer-after-mastectomy\" class=\"medical medical_review\">&quot;Management of locoregional recurrence of breast cancer after mastectomy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=breast-lymphoma\" class=\"medical medical_review\">&quot;Breast lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=complications-of-reconstructive-and-aesthetic-breast-surgery#H24299623\" class=\"medical medical_review\">&quot;Complications of reconstructive and aesthetic breast surgery&quot;, section on 'Anaplastic large cell lymphoma'</a> and <a href=\"topic.htm?path=implant-based-breast-reconstruction-and-augmentation#H1616409128\" class=\"medical medical_review\">&quot;Implant-based breast reconstruction and augmentation&quot;, section on 'Concerns over breast implants'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-benign-breast-disease\" class=\"medical medical_review\">&quot;Overview of benign breast disease&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=breast-cellulitis-and-other-skin-disorders-of-the-breast\" class=\"medical medical_review\">&quot;Breast cellulitis and other skin disorders of the breast&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H11243257\"><span class=\"h1\">STAGING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Staging of the extent of tumor spread provides a means for formally assigning prognostic categories and is of enormous value in comparing treatment results from individual treatment centers. Treatment decisions are strongly influenced by the stage at initial diagnosis.</p><p>The most commonly used staging system for breast sarcomas is the same as that used for sarcomas arising at other sites, from the combined American Joint Committee on Cancer <span class=\"nowrap\">(AJCC)/International</span> Union Against Cancer (UICC) (<a href=\"image.htm?imageKey=ONC%2F110711\" class=\"graphic graphic_table graphicRef110711 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/74\" class=\"abstract_t\">74</a>]. TNM stage incorporates histologic grade (G), tumor size (T), depth of the tumor (superficial or deep), lymph node metastases (N), and the presence or absence of distant metastases (M) to characterize four stage groupings, I through IV. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H351701269\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'Staging'</a>.) </p><p>Nodal status is less informative than it is with epithelial breast cancers. As with soft tissue sarcomas arising at other sites, regional lymph node metastases are uncommon, with the exception of certain histologies, including angiosarcoma. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H7798376\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'Regional nodes'</a>.)</p><p class=\"headingAnchor\" id=\"H267358007\"><span class=\"h2\">Disease spread and the staging workup</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The lungs are the predominant metastatic site for the majority of soft tissue sarcomas (except for GIST, some forms of liposarcoma, and other rare sarcoma subtypes), including those arising in the breast. Computed tomography (CT) of the chest should be obtained for all newly diagnosed patients with a soft tissue sarcoma in guidelines from the Society of Surgical Oncology [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/75\" class=\"abstract_t\">75</a>] and the <a href=\"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp&amp;token=yAtQYciL7uywmW3eRYUeJ4aK0dRx4JGGLufx5fCsL/3GEnpty51PpRmw8L7qDt7YvrmdE8jMEGNSa6WMQQkRzhg6guWN9QugGEPeOqp3ljo=&amp;TOPIC_ID=811\" target=\"_blank\" class=\"external\">National Comprehensive Cancer Network (NCCN)</a>. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H12227107\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'Pattern of spread'</a>.)</p><p>Positron emission tomography with fluorodeoxyglucose (FDG-PET) may be useful to detect sites of metastatic disease, but its role as an adjunct to or in place of conventional imaging is unclear [<a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76\" class=\"abstract_t\">76</a>]. PET scanning with or without integrated CT <span class=\"nowrap\">(PET/CT)</span> is not routinely recommended as a component of the initial staging workup of soft tissue sarcoma of the breast or any other site for evaluation of either pulmonary or extrapulmonary metastatic disease. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H12227163\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'PET and PET/CT'</a>.)</p><p>Specific tests may be recommended for certain histologies:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abdominopelvic CT should be obtained and MRI of the entire spine should be considered in patients with high grade round <span class=\"nowrap\">cell/myxoid</span> liposarcomas due to their propensity to metastasize to the retroperitoneum and spine.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bone scan should be obtained and central nervous system (CNS) imaging should be considered in patients with angiosarcoma given the propensity of this subtype to involve bone and CNS.</p><p/><p>A more extensive discussion of the diagnostic and staging for soft tissue sarcomas is presented elsewhere. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H12227121\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'Diagnostic evaluation'</a> and <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma#H351701269\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;, section on 'Staging'</a>.)</p><p class=\"headingAnchor\" id=\"H3399099\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Breast sarcomas are primary nonepithelial malignancies arising from the connective tissue within the breast. Sarcomas of the breast can arise de novo (primary) or as a result of treatment for another malignancy (secondary, therapy-related), usually with radiation therapy (RT). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A causative factor cannot be identified in many breast sarcomas. Predisposing genetic conditions can sometimes be identified, but these are uncommon. Secondary or treatment-related breast sarcomas most frequently arise following breast cancer treatment, but can also be associated with RT for other malignancies in which the breast or chest wall is included in the radiated field. Another contributory factor is chronic lymphedema. (See <a href=\"#H2\" class=\"local\">'Risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Core biopsy is generally considered the procedure of choice for the definitive diagnosis of a breast sarcoma. Fine needle aspiration is strongly discouraged as it has a low diagnostic accuracy for sarcoma and a false negative result may lead to a delay in diagnosis. For cutaneous lesions, multiple punch biopsies of the skin may provide a diagnosis. (See <a href=\"#H3321882\" class=\"local\">'Biopsy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histologic review by an experienced soft tissue pathologist is critical in making the diagnosis and determining histologic subtype. In general, fibrosarcomas, angiosarcomas, and pleomorphic sarcomas comprise the major subtypes. (See <a href=\"#H529562\" class=\"local\">'Histologic classification'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest computed tomography should be obtained in all newly diagnosed patients since the lungs are the predominant metastatic site. PET or integrated <span class=\"nowrap\">PET/CT</span> is not routinely recommended as a component of the initial staging workup of soft tissue sarcoma for evaluation of either pulmonary or extrapulmonary metastatic disease. In addition, abdominopelvic CT should be obtained and MRI of the entire spine should be considered in patients with high grade round <span class=\"nowrap\">cell/myxoid</span> liposarcomas due to their propensity to metastasize to the retroperitoneum and spine. Bone scan should be obtained and central nervous system (CNS) imaging should be considered in patients with angiosarcoma given the propensity of this subtype to involve bone and CNS. (See <a href=\"#H267358007\" class=\"local\">'Disease spread and the staging workup'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/1\" class=\"nounderline abstract_t\">Berg JW, Hutter RV. Breast cancer. Cancer 1995; 75:257.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/2\" class=\"nounderline abstract_t\">Karlsson P, Holmberg E, Johansson KA, et al. Soft tissue sarcoma after treatment for breast cancer. Radiother Oncol 1996; 38:25.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/3\" class=\"nounderline abstract_t\">Brady MS, Garfein CF, Petrek JA, Brennan MF. Post-treatment sarcoma in breast cancer patients. Ann Surg Oncol 1994; 1:66.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/4\" class=\"nounderline abstract_t\">Lagrange JL, Ramaioli A, Chateau MC, et al. Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the F&eacute;d&eacute;ration Nationale des Centres de Lutte Contre le Cancer. Radiology 2000; 216:197.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/5\" class=\"nounderline abstract_t\">Blanchard DK, Reynolds C, Grant CS, et al. Radiation-induced breast sarcoma. Am J Surg 2002; 184:356.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/6\" class=\"nounderline abstract_t\">Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 2001; 92:172.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/7\" class=\"nounderline abstract_t\">McGowan TS, Cummings BJ, O'Sullivan B, et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys 2000; 46:383.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/8\" class=\"nounderline abstract_t\">Russell WO, Cohen J, Enzinger F, et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977; 40:1562.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/9\" class=\"nounderline abstract_t\">Zelek L, Llombart-Cussac A, Terrier P, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003; 21:2583.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/10\" class=\"nounderline abstract_t\">Cozen W, Bernstein L, Wang F, et al. The risk of angiosarcoma following primary breast cancer. Br J Cancer 1999; 81:532.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/11\" class=\"nounderline abstract_t\">Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002; 52:1231.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/12\" class=\"nounderline abstract_t\">Terrier P, Terrier-Lacombe MJ, Mouriesse H, et al. Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. Breast Cancer Res Treat 1989; 13:39.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/13\" class=\"nounderline abstract_t\">Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer 2004; 91:237.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/14\" class=\"nounderline abstract_t\">Blanchard DK, Reynolds CA, Grant CS, Donohue JH. Primary nonphylloides breast sarcomas. Am J Surg 2003; 186:359.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/15\" class=\"nounderline abstract_t\">Pandey M, Mathew A, Abraham EK, Rajan B. Primary sarcoma of the breast. J Surg Oncol 2004; 87:121.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/16\" class=\"nounderline abstract_t\">Granier G, Lemoine MC, Mares P, et al. [Primary angiosarcoma of the male breast]. Ann Pathol 2005; 25:235.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/17\" class=\"nounderline abstract_t\">Al-Benna S, Poggemann K, Steinau HU, Steinstraesser L. Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat 2010; 122:619.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/18\" class=\"nounderline abstract_t\">May DS, Stroup NE. The incidence of sarcomas of the breast among women in the United States, 1973-1986. Plast Reconstr Surg 1991; 87:193.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/19\" class=\"nounderline abstract_t\">Marchal C, Weber B, de Lafontan B, et al. Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Int J Radiat Oncol Biol Phys 1999; 44:113.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/20\" class=\"nounderline abstract_t\">Vorburger SA, Xing Y, Hunt KK, et al. Angiosarcoma of the breast. Cancer 2005; 104:2682.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/21\" class=\"nounderline abstract_t\">Shet T, Malaviya A, Nadkarni M, et al. Primary angiosarcoma of the breast: observations in Asian Indian women. J Surg Oncol 2006; 94:368.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/22\" class=\"nounderline abstract_t\">Sher T, Hennessy BT, Valero V, et al. Primary angiosarcomas of the breast. Cancer 2007; 110:173.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/23\" class=\"nounderline abstract_t\">Moore MP, Kinne DW. Breast sarcoma. Surg Clin North Am 1996; 76:383.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/24\" class=\"nounderline abstract_t\">STEWART FW, TREVES N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1948; 1:64.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/25\" class=\"nounderline abstract_t\">Sheth GR, Cranmer LD, Smith BD, et al. Radiation-induced sarcoma of the breast: a systematic review. Oncologist 2012; 17:405.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/26\" class=\"nounderline abstract_t\">Penel N, Grosjean J, Robin YM, et al. Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. Sarcoma 2008; 2008:459386.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/27\" class=\"nounderline abstract_t\">Kuttesch JF Jr, Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996; 14:2818.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/28\" class=\"nounderline abstract_t\">Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337:949.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/29\" class=\"nounderline abstract_t\">Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337:956.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/30\" class=\"nounderline abstract_t\">Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353:1641.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/31\" class=\"nounderline abstract_t\">Rubino C, Shamsaldin A, L&ecirc; MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 2005; 89:277.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/32\" class=\"nounderline abstract_t\">O'Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010; 28:1232.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/33\" class=\"nounderline abstract_t\">Kirova YM, Vilcoq JR, Asselain B, et al. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer 2005; 104:856.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/34\" class=\"nounderline abstract_t\">Taghian A, de Vathaire F, Terrier P, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 1991; 21:361.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/35\" class=\"nounderline abstract_t\">Zucali R, Merson M, Placucci M, et al. Soft tissue sarcoma of the breast after conservative surgery and irradiation for early mammary cancer. Radiother Oncol 1994; 30:271.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/36\" class=\"nounderline abstract_t\">Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:915.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/37\" class=\"nounderline abstract_t\">Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer 2009; 115:4055.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/38\" class=\"nounderline abstract_t\">Laskin WB, Silverman TA, Enzinger FM. Postradiation soft tissue sarcomas. An analysis of 53 cases. Cancer 1988; 62:2330.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/39\" class=\"nounderline abstract_t\">Davidson T, Westbury G, Harmer CL. Radiation-induced soft-tissue sarcoma. Br J Surg 1986; 73:308.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/40\" class=\"nounderline abstract_t\">Chahin F, Paramesh A, Dwivedi A, et al. Angiosarcoma of the breast following breast preservation therapy and local radiation therapy for breast cancer. Breast J 2001; 7:120.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/41\" class=\"nounderline abstract_t\">Strobbe LJ, Peterse HL, van Tinteren H, et al. Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 1998; 47:101.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/42\" class=\"nounderline abstract_t\">Billings SD, McKenney JK, Folpe AL, et al. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol 2004; 28:781.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/43\" class=\"nounderline abstract_t\">Sessions SC, Smink RD Jr. Cutaneous angiosarcoma of the breast after segmental mastectomy and radiation therapy. Arch Surg 1992; 127:1362.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/44\" class=\"nounderline abstract_t\">Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol 1994; 102:757.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/45\" class=\"nounderline abstract_t\">Krueger EA, Fraass BA, McShan DL, et al. Potential gains for irradiation of chest wall and regional nodes with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56:1023.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/46\" class=\"nounderline abstract_t\">Woodward AH, Ivins JC, Soule EH. Lymphangiosarcoma arising in chronic lymphedematous extremities. Cancer 1972; 30:562.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/47\" class=\"nounderline abstract_t\">Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997; 24:504.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/48\" class=\"nounderline abstract_t\">McGregor GI, Knowling MA, Este FA. Sarcoma and Cystosarcoma phyllodes tumors of the breast--a retrospective review of 58 cases. Am J Surg 1994; 167:477.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/49\" class=\"nounderline abstract_t\">Confavreux C, Lurkin A, Mitton N, et al. Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. Eur J Cancer 2006; 42:2715.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/50\" class=\"nounderline abstract_t\">Bousquet G, Confavreux C, Magn&eacute; N, et al. Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol 2007; 85:355.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51\" class=\"nounderline abstract_t\">Rosen PP, Kimmel M, Ernsberger D. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer 1988; 62:2145.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/52\" class=\"nounderline abstract_t\">Donnell RM, Rosen PP, Lieberman PH, et al. Angiosarcoma and other vascular tumors of the breast. Am J Surg Pathol 1981; 5:629.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/53\" class=\"nounderline abstract_t\">Luini A, Gatti G, Diaz J, et al. Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. Breast Cancer Res Treat 2007; 105:81.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/54\" class=\"nounderline abstract_t\">Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol 2008; 32:1896.</a></li><li class=\"breakAll\">Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. World Health Organization Classification of tumours of soft tissue and bone, 4th ed, IARC Press, Lyon 2013.</li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/56\" class=\"nounderline abstract_t\">Deyrup AT, Weiss SW. Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world. Histopathology 2006; 48:42.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/57\" class=\"nounderline abstract_t\">Gutman H, Pollock RE, Ross MI, et al. Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery 1994; 116:505.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/58\" class=\"nounderline abstract_t\">Pollard SG, Marks PV, Temple LN, Thompson HH. Breast sarcoma. A clinicopathologic review of 25 cases. Cancer 1990; 66:941.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/59\" class=\"nounderline abstract_t\">North JH Jr, McPhee M, Arredondo M, Edge SB. Sarcoma of the breast: implications of the extent of local therapy. Am Surg 1998; 64:1059.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/60\" class=\"nounderline abstract_t\">Shabahang M, Franceschi D, Sundaram M, et al. Surgical management of primary breast sarcoma. Am Surg 2002; 68:673.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/61\" class=\"nounderline abstract_t\">Morgan EA, Kozono DE, Wang Q, et al. Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. Ann Surg Oncol 2012; 19:3801.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/62\" class=\"nounderline abstract_t\">Smith TB, Gilcrease MZ, Santiago L, et al. Imaging features of primary breast sarcoma. AJR Am J Roentgenol 2012; 198:W386.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/63\" class=\"nounderline abstract_t\">Yang WT, Muttarak M, Ho LW. Nonmammary malignancies of the breast: ultrasound, CT, and MRI. Semin Ultrasound CT MR 2000; 21:375.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/64\" class=\"nounderline abstract_t\">Schnarkowski P, Kessler M, Arnholdt H, Helmberger T. Angiosarcoma of the breast: mammographic, sonographic, and pathological findings. Eur J Radiol 1997; 24:54.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/65\" class=\"nounderline abstract_t\">Liberman L, Dershaw DD, Kaufman RJ, Rosen PP. Angiosarcoma of the breast. Radiology 1992; 183:649.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/66\" class=\"nounderline abstract_t\">Williams EV, Banerjee D, Dallimore N, Monypenny IJ. Angiosarcoma of the breast following radiation therapy. Eur J Surg Oncol 1999; 25:221.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/67\" class=\"nounderline abstract_t\">Fant J, Grant M, May S, et al. Angiosarcoma of the breast: mammographic, clinical, and pathologic correlation. Breast J 2003; 9:252.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/68\" class=\"nounderline abstract_t\">Hodgson NC, Bowen-Wells C, Moffat F, et al. Angiosarcomas of the breast: a review of 70 cases. Am J Clin Oncol 2007; 30:570.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/69\" class=\"nounderline abstract_t\">Mills TD, Vinnicombe SJ, Wells CA, Carpenter R. Angiosarcoma of the breast after wide local excision and radiotherapy for breast carcinoma. Clin Radiol 2002; 57:63.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/70\" class=\"nounderline abstract_t\">Sanders LM, Groves AC, Schaefer S. Cutaneous angiosarcoma of the breast on MRI. AJR Am J Roentgenol 2006; 187:W143.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/71\" class=\"nounderline abstract_t\">Yang WT, Hennessy BT, Dryden MJ, et al. Mammary angiosarcomas: imaging findings in 24 patients. Radiology 2007; 242:725.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/72\" class=\"nounderline abstract_t\">Glazebrook KN, Morton MJ, Reynolds C. Vascular tumors of the breast: mammographic, sonographic, and MRI appearances. AJR Am J Roentgenol 2005; 184:331.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/73\" class=\"nounderline abstract_t\">Marchant LK, Orel SG, Perez-Jaffe LA, et al. Bilateral angiosarcoma of the breast on MR imaging. AJR Am J Roentgenol 1997; 169:1009.</a></li><li class=\"breakAll\">AJCC (American Joint Committee on Cancer). Cancer Staging Manual, 7th edition, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.291.</li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/75\" class=\"nounderline abstract_t\">Pollack R, Brennan M, Lawrence W Jr. Society of Surgical Oncology practice guidelines. Soft-tissue sarcoma surgical practice guidelines. Oncology (Williston Park) 1997; 11:1327.</a></li><li><a href=\"https://www.uptodate.com/contents/breast-sarcoma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76\" class=\"nounderline abstract_t\">Bakheet SM, Powe J, Ezzat A, et al. F-18 FDG whole-body positron emission tomography scan in primary breast sarcoma. Clin Nucl Med 1998; 23:604.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 811 Version 30.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H3399099\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3320653\" id=\"outline-link-H3320653\">EPIDEMIOLOGY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">RISK FACTORS</a><ul><li><a href=\"#H30564621\" id=\"outline-link-H30564621\">Ionizing radiation</a><ul><li><a href=\"#H9239667\" id=\"outline-link-H9239667\">- Breast cancer survivors</a></li></ul></li><li><a href=\"#H751986\" id=\"outline-link-H751986\">Lymphedema</a></li><li><a href=\"#H4672806\" id=\"outline-link-H4672806\">Inherited conditions</a></li><li><a href=\"#H4672598\" id=\"outline-link-H4672598\">Environmental factors</a></li></ul></li><li><a href=\"#H529562\" id=\"outline-link-H529562\">HISTOLOGIC CLASSIFICATION</a><ul><li><a href=\"#H10858421\" id=\"outline-link-H10858421\">Grading</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL FEATURES AND DIAGNOSIS</a><ul><li><a href=\"#H4675516\" id=\"outline-link-H4675516\">Diagnosis</a><ul><li><a href=\"#H11242979\" id=\"outline-link-H11242979\">- Imaging</a></li><li><a href=\"#H3321882\" id=\"outline-link-H3321882\">- Biopsy</a></li><li><a href=\"#H4672563\" id=\"outline-link-H4672563\">- Laboratory studies</a></li></ul></li></ul></li><li><a href=\"#H4672367\" id=\"outline-link-H4672367\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H11243257\" id=\"outline-link-H11243257\">STAGING</a><ul><li><a href=\"#H267358007\" id=\"outline-link-H267358007\">Disease spread and the staging workup</a></li></ul></li><li><a href=\"#H3399099\" id=\"outline-link-H3399099\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/811|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=RADIOL/86977\" class=\"graphic graphic_diagnosticimage\">- Angiosarcoma of the breast</a></li></ul></li><li><div id=\"ONC/811|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/86979\" class=\"graphic graphic_picture\">- Gross images of breast angiosarcoma</a></li><li><a href=\"image.htm?imageKey=ONC/86926\" class=\"graphic graphic_picture\">- Microscopic images of secondary breast angiosarcoma</a></li></ul></li><li><div id=\"ONC/811|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/61730\" class=\"graphic graphic_table\">- Sarcoma after breast CA RT</a></li><li><a href=\"image.htm?imageKey=ONC/110711\" class=\"graphic graphic_table\">- STS extrem and trunk TNM 2017</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=aids-related-kaposi-sarcoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-radiation-therapy-for-women-with-newly-diagnosed-non-metastatic-breast-cancer\" class=\"medical medical_review\">Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=breast-cellulitis-and-other-skin-disorders-of-the-breast\" class=\"medical medical_review\">Breast cellulitis and other skin disorders of the breast</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=breast-lymphoma\" class=\"medical medical_review\">Breast lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=breast-sarcoma-treatment\" class=\"medical medical_review\">Breast sarcoma: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-peripheral-lymphedema\" class=\"medical medical_review\">Clinical features and diagnosis of peripheral lymphedema</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-staging-of-newly-diagnosed-breast-cancer\" class=\"medical medical_review\">Clinical features, diagnosis, and staging of newly diagnosed breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of familial adenomatous polyposis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma\" class=\"medical medical_review\">Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=complications-of-reconstructive-and-aesthetic-breast-surgery\" class=\"medical medical_review\">Complications of reconstructive and aesthetic breast surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=desmoid-tumors-epidemiology-risk-factors-molecular-pathogenesis-clinical-presentation-diagnosis-and-local-therapy\" class=\"medical medical_review\">Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=implant-based-breast-reconstruction-and-augmentation\" class=\"medical medical_review\">Implant-based breast reconstruction and augmentation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=inflammatory-breast-cancer-clinical-features-and-treatment\" class=\"medical medical_review\">Inflammatory breast cancer: Clinical features and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=li-fraumeni-syndrome\" class=\"medical medical_review\">Li-Fraumeni syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-locoregional-recurrence-of-breast-cancer-after-breast-conserving-therapy\" class=\"medical medical_review\">Management of locoregional recurrence of breast cancer after breast conserving therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-locoregional-recurrence-of-breast-cancer-after-mastectomy\" class=\"medical medical_review\">Management of locoregional recurrence of breast cancer after mastectomy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-benign-breast-disease\" class=\"medical medical_review\">Overview of benign breast disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenetic-factors-in-soft-tissue-and-bone-sarcomas\" class=\"medical medical_review\">Pathogenetic factors in soft tissue and bone sarcomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathology-of-breast-cancer\" class=\"medical medical_review\">Pathology of breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=patterns-of-relapse-and-long-term-complications-of-therapy-in-breast-cancer-survivors\" class=\"medical medical_review\">Patterns of relapse and long-term complications of therapy in breast cancer survivors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=phyllodes-tumors-of-the-breast\" class=\"medical medical_review\">Phyllodes tumors of the breast</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiation-therapy-techniques-for-newly-diagnosed-non-metastatic-breast-cancer\" class=\"medical medical_review\">Radiation therapy techniques for newly diagnosed, non-metastatic breast cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=second-malignancies-after-treatment-of-classical-hodgkin-lymphoma\" class=\"medical medical_review\">Second malignancies after treatment of classical Hodgkin lymphoma</a></li></ul></div></div>","javascript":null}